IAD leverages Intrexon’s proprietary ActoBiotics® platform
to deliver therapeutic molecules selectively to the oral and gastrointestinal tract for the treatment of oral, gastrointestinal, metabolic, allergic and autoimmune diseases. IAD seeks to develop orally administered ActoBiotics®
biotherapeutics that enable treatment opportunities not achievable through customary mechanisms like injectable medicines and permitting ease of administration for patients.
technology, IAD is working to develop safe, efficacious therapeutic solutions for human and animal health applications. Key areas for IAD include oral mucositis, inflammatory bowel disease, allergy, type-1 diabetes, celiac disease, porcine growth and nutrition. IAD focuses on providing proof-of-concept in animal models, establishing non-clinical PK/PD/safety data information for regulatory submissions and manufacturing of (non-)GMP batches for (non-)clinical experimentation.
IAD, a division of Intrexon Actobiotics NV, subsidiary of Intrexon Corporation
Technologiepark 4 9052 Gent Belgium
Tel: +32 9 261.06.00 | E-mail: IA.email@example.com